Trial Profile
A double-blind, placebo-control, randomized, dose-finding phase II/III study to evaluate the efficacy and safety of TAC-202 in patients with chronic idiopathic urticaria
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 07 Jan 2022
Price :
$35
*
At a glance
- Drugs Bilastine (Primary)
- Indications Urticaria
- Focus Therapeutic Use
- Sponsors Taiho Pharmaceutical
- 13 Jan 2015 New trial record